FMP

FMP

Enter

ERYP.PA - ERYTECH Pharma S.A.

Equity Value of ERYTECH Pharma S.A.(ERYP.PA), ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based thera

photo-url-https://financialmodelingprep.com/image-stock/ERYP.PA.png

ERYTECH Pharma S.A.

ERYP.PA

EURONEXT

Inactive Equity

ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine cancers. The company was incorporated in 2004 and is headquartered in Lyon, France.

0.801 EUR

0.002 (0.25%)

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep